目的 探討喘可治聯(lián)合多索茶堿治療慢性阻塞性肺疾病急性發(fā)作期的臨床療效。方法 選取2016年6月-2017年6月在西寧市第三人民醫(yī)院治療的慢性阻塞性肺疾病急性發(fā)作期患者166例，隨機(jī)分成對(duì)照組和治療組，每組各83例。對(duì)照組患者靜脈滴注注射用多索茶堿，0.2 g加入5%葡萄糖注射液100 mL，1次/d；治療組在對(duì)照組基礎(chǔ)上肌肉注射喘可治注射液，4 mL/次，2次/d。兩組患者均連續(xù)用藥7 d。觀察兩組患者臨床療效，比較治療前后兩組患者主要臨床癥狀消失時(shí)間和住院時(shí)間及肺功能指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為86.75%和97.59%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者呼吸困難癥狀消失時(shí)間、咳嗽消失時(shí)間和住院時(shí)間均顯著短于對(duì)照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者肺功能指標(biāo)第一秒用力呼氣容積（FEV1）、最大呼氣流量（PEF）和FEV1/FVC均顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者的肺功能指標(biāo)顯著高于對(duì)照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 喘可治聯(lián)合多索茶堿治療慢性阻塞性肺疾病急性發(fā)作期患者臨床療效顯著，安全性好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of chuankezhi combined with doxofylline in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (166 cases) with acute exacerbation of chronic obstructive pulmonary disease in the Third People's Hospital of Xining from June 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 83 cases. Patients in the control group were iv administered with Doxofylline for injection, 0.2 g added into 5% glucose injection 100 mL, once daily. Patients in the treatment group were im administered with Chuankezhi Injection on the basis of the control group, 40 mL/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms and hospitalization time, the pulmonary function indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.75% and 97.59%, respectively, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of dyspnea and cough, the hospitalization time in the treatment group was significantly less than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the FEV1, PEF and FEV1/FVC in two groups were significantly increased, and there were differences in the same group (P < 0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion chuankezhi combined with doxofylline has significant clinical efficacy in treatment of acute exacerbation of chronic obstructive pulmonary disease with higher safety, which has a certain clinical application value.